https://scholars.lib.ntu.edu.tw/handle/123456789/568945
標題: | Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Anti-inflammatory Drugs: A Nested Case-Control Study | 作者: | Hou P.-C. FANG-JU LIN SHIN YI LIN TZUNG-JENG HWANG CHI-CHUAN WANG |
公開日期: | 2021 | 卷: | 55 | 期: | 8 | 起(迄)頁: | 941-948 | 來源出版物: | Annals of Pharmacotherapy | 摘要: | Background: Whereas previous studies found that concomitant antidepressant and nonsteroidal anti-inflammatory drug (NSAIDs) use may increase the risk of gastrointestinal bleeding, either drug alone increases the risk of intracranial hemorrhage (ICH). Objective: To assess the risk for ICH in patients on concomitant treatment with antidepressants and NSAIDs. Methods: This was a nested case-control study using national insurance claims data in Taiwan between 2005 and 2013. Drug exposure was measured and compared during 3 time windows: 1 to 30, 31 to 60, and 61 to 90 days before the index date, which is the date of the ICH event. Both traditional and newer-generation antidepressants were considered in this study. Results: Patients exposed to both antidepressants and NSAIDs 1 to 30 days before the index date presented a 50% increased odds of developing ICH (OR: 1.53; 95% CI: 1.31-1.80) compared with patients receiving antidepressants alone. Specifically, the concomitant use of nonselective NSAIDs and antidepressants increased these odds compared with antidepressants alone (OR: 1.56; 95% CI: 1.31-1.84), but using a selective cyclooxygenase-2 inhibitor with antidepressant did not alter ICH risk. Regarding antidepressant class, newer-generation antidepressants generally increase the odds of developing ICH by 60% when used concomitantly with NSAIDs. Conclusion and Relevance: Our results suggested that the concomitant use of antidepressants and NSAIDs was associated with an increased odds of developing ICH. NSAIDs, especially nonselective NSAIDs, and serotonergic antidepressants played an important role in this risk. Given the prevalent use of these 2 classes of drugs, this potential drug interaction deserves more attention. ? The Author(s) 2020. |
URI: | 2-s2.0-85097511420 https://scholars.lib.ntu.edu.tw/handle/123456789/568945 |
ISSN: | 10600280 | DOI: | 10.1177/1060028020980417 | SDG/關鍵字: | agomelatine; amfebutamone; angiotensin receptor antagonist; anticoagulant agent; antidepressant agent; antidiabetic agent; antilipemic agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; cyclooxygenase 2 inhibitor; dipeptidyl carboxypeptidase inhibitor; diuretic agent; insulin; mirtazapine; moclobemide; neuroleptic agent; nonsteroid antiinflammatory agent; serotonin noradrenalin reuptake inhibitor; serotonin uptake inhibitor; trazodone; tricyclic antidepressant agent; antidepressant agent; drug; nonsteroid antiinflammatory agent; adult; age; Article; brain hemorrhage; case control study; comorbidity; controlled study; depression; drug exposure; female; high risk patient; human; ICD-9-CM; major clinical study; male; national health insurance; risk assessment; sensitivity analysis; sex difference; brain hemorrhage; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Case-Control Studies; Humans; Intracranial Hemorrhages; Pharmaceutical Preparations |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。